enVVeno Medical Corp
NASDAQ:NVNO

Watchlist Manager
enVVeno Medical Corp Logo
enVVeno Medical Corp
NASDAQ:NVNO
Watchlist
Price: 0.342 USD
Market Cap: 6.9m USD

Operating Margin

0%
Current
No historical data
Comparison unavailable

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
$0
/
$0

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
$0
/
$0

Peer Comparison

Country Company Market Cap Operating
Margin
US
enVVeno Medical Corp
NASDAQ:NVNO
6.9m USD
Loading...
US
Abbott Laboratories
NYSE:ABT
211.7B USD
Loading...
US
Intuitive Surgical Inc
NASDAQ:ISRG
191.8B USD
Loading...
US
Stryker Corp
NYSE:SYK
139.1B USD
Loading...
US
Boston Scientific Corp
NYSE:BSX
130.5B USD
Loading...
IE
Medtronic PLC
NYSE:MDT
124B USD
Loading...
US
Becton Dickinson and Co
NYSE:BDX
59.1B USD
Loading...
DE
Siemens Healthineers AG
XETRA:SHL
49.5B EUR
Loading...
US
IDEXX Laboratories Inc
NASDAQ:IDXX
57.2B USD
Loading...
US
Edwards Lifesciences Corp
NYSE:EW
49B USD
Loading...
US
Resmed Inc
NYSE:RMD
37.6B USD
Loading...
No Stocks Found

Market Distribution

Not Available
No Country distribution data available for this multiple

enVVeno Medical Corp
Glance View

Market Cap
6.9m USD
Industry
Health Care

enVVeno Medical Corp. is a development stage medical device company, which develops tissue based solutions that are designed to be life sustaining or life enhancing for patients with cardiovascular disease, and peripheral arterial and venous disease. The company is headquartered in Irvine, California and currently employs 24 full-time employees. The company went IPO on 2018-05-31. The firm is focused on improving the standard of care in the treatment of venous disease. The firm is focused on developing tissue-based solutions that are designed for patients with chronic venous insufficiency (CVI). Its lead product, VenoValve, is a porcine based device being developed to surgically implanted in the deep venous system of the leg to treat severe CVI, including the potential to heal recurring venous leg ulcers. The VenoValve is designed to be implanted into the femoral vein of the patient in an open surgical procedure via a five-to-six-inch incision in the upper thigh. The VenoValve is being evaluated in the surgical anti-reflux venous valve endoprosthesis (SAVVE) United States clinical trial. In addition to the VenoValve, the Company is focused on the development of a second device, enVVe, for the treatment of venous disease.

NVNO Intrinsic Value
Not Available
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Back to Top